Olympus Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Olympus kazanç ve gelirin sırasıyla yıllık 14.4% ve 5.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 16% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 16.1% olacağı tahmin edilmektedir.

Anahtar bilgiler

14.4%

Kazanç büyüme oranı

16.0%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	14.2%
Gelir büyüme oranı	5.1%
Gelecekteki özkaynak getirisi	16.1%
Analist kapsamı	Good
Son güncelleme	18 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:OLY - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (JPY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	1,117,050	158,643	115,326	207,811	13
3/31/2026	1,055,588	142,517	106,331	192,771	14
3/31/2025	1,003,968	117,529	71,114	173,486	14
9/30/2024	973,595	87,726	81,759	147,854	N/A
6/30/2024	966,046	27,884	56,269	118,734	N/A
3/31/2024	936,210	26,610	-22,259	42,365	N/A
12/31/2023	916,092	39,468	-36,583	30,686	N/A
9/30/2023	901,507	56,534	11,195	80,406	N/A
6/30/2023	875,586	126,381	-1,680	72,238	N/A
3/31/2023	881,923	137,809	27,867	98,490	N/A
12/31/2022	933,645	137,623	45,131	109,416	N/A
9/30/2022	925,858	126,848	47,185	107,203	N/A
6/30/2022	891,410	121,912	60,183	119,188	N/A
3/31/2022	868,867	115,742	107,958	169,729	N/A
12/31/2021	793,727	95,274	85,693	150,356	N/A
9/30/2021	774,113	98,063	90,544	155,506	N/A
6/30/2021	785,411	84,467	78,484	139,415	N/A
3/31/2021	730,544	65,599	64,895	124,122	N/A
12/31/2020	715,924	46,443	55,563	116,827	N/A
9/30/2020	724,722	41,459	42,698	103,723	N/A
6/30/2020	752,176	42,855	50,303	113,526	N/A
3/31/2020	797,411	51,670	67,615	133,544	N/A
12/31/2019	807,887	60,758	72,843	136,095	N/A
9/30/2019	801,202	49,704	44,493	106,769	N/A
6/30/2019	795,193	33,469	8,586	70,321	N/A
3/31/2019	793,862	8,147	5,477	66,943	N/A
12/31/2018	795,479	15,554	9,623	71,514	N/A
9/30/2018	798,915	21,732	15,843	79,978	N/A
6/30/2018	795,205	30,324	N/A	100,036	N/A
3/31/2018	786,497	57,064	N/A	95,146	N/A
12/31/2017	786,608	85,083	N/A	N/A	N/A
9/30/2017	767,508	85,830	N/A	91,430	N/A
6/30/2017	751,458	79,716	N/A	N/A	N/A
3/31/2017	748,050	78,191	N/A	90,194	N/A
12/31/2016	745,543	60,888	N/A	N/A	N/A
9/30/2016	758,777	48,983	N/A	35,146	N/A
6/30/2016	785,444	54,390	N/A	N/A	N/A
3/31/2016	804,578	62,594	N/A	48,621	N/A
12/31/2015	807,197	2,188	N/A	N/A	N/A
9/30/2015	805,432	4,742	N/A	92,093	N/A
6/30/2015	785,230	-144	N/A	N/A	N/A
3/31/2015	764,671	-8,737	N/A	66,811	N/A
12/31/2014	749,627	39,710	N/A	N/A	N/A
9/30/2014	734,469	43,896	N/A	72,544	N/A
6/30/2014	721,070	23,599	N/A	N/A	N/A
3/31/2014	713,286	13,627	N/A	72,388	N/A
12/31/2013	696,297	6,239	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: OLY 'nin tahmini kazanç büyümesi (yıllık 14.4% ) tasarruf oranının ( 1% ) üzerindedir.

Kazançlar ve Piyasa: OLY şirketinin kazançlarının (yıllık 14.4% ) German pazarından (yıllık 21.1% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: OLY şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: OLY şirketinin gelirinin (yıllık 5.1% ) German pazarından (yıllık 5.7% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: OLY şirketinin gelirinin (yıllık 5.1% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: OLY 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 16.1 %).

Olympus Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Olympus Corporation Revises Consolidated Revenue Guidance for the Fiscal Year Ending March 31, 2024

Olympus Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Olympus Corporation Reiterates Consolidated Financial Guidance for the Fiscal Year Ending March 2024

Olympus Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Olympus Corporation Revises Consolidated Financial Guidance for the Fiscal Year Ending March 31, 2022

Olympus Corporation Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022

Recent updates

Olympus Corporation Announces Resignation of Stefan Kaufmann as Chief Executive Officer, Effective October 28, 2024

Olympus Corporation Announces Executive Changes, Effective October 1, 2024

Olympus Corporation, Annual General Meeting, Jun 26, 2024

Olympus Corporation (TSE:7733) announces an Equity Buyback for 60,000,000 shares, representing 5.15% for ¥100,000 million.

Olympus Corporation to Report Q1, 2025 Results on Aug 07, 2024

Olympus Corporation Revises Consolidated Revenue Guidance for the Fiscal Year Ending March 31, 2024

Olympus Corporation Announces Executive Changes

Olympus Corporation (TSE:7733) completed the acquisition of Taewoong Medical Co. Ltd. from Kyong-min Shin and others.

Olympus Corporation Announces Study Results Show the S Sustained Clinical Benefits of Spiration Valve System At 24 Months

Olympus Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Olympus Corporation (TSE:7733) announces an Equity Buyback for 53,000,000 shares, representing 4.34% for ¥80,000 million.

Olympus Corporation Announces Market Launch of EVIS X1 Endoscopy System

Olympus Corporation Announces the Launch of the Vathin E-SteriScope

Olympus Corporation Announces Publication of Study Data Demonstrating That the Minimally Invasive Itind™? Treatment Provides Long-Lasting Relief of More Than Four Years

Olympus Corporation to Report Q3, 2024 Results on Feb 14, 2024

Olympus Corporation Reiterates Consolidated Financial Guidance for the Fiscal Year Ending March 2024

Olympus Names Wenlei Yang the Newly Established Chief Diversity, Equity and Inclusion Officer

Olympus Corporation, Annual General Meeting, Jun 27, 2023

Olympus Corporation Set to Demonstrate Newest Endoscopy System At DDW

Olympus Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Olympus Corporation (TSE:7733) announces an Equity Buyback for 21,000,000 shares, representing 1.65% for ¥50,000 million.

Olympus Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Olympus Launches VISERA ELITE III Surgical Visualization Platform

Bain Capital Private Equity, LP entered into a definitive agreement to acquire Scientific Solutions Business of Olympus Corporation from Olympus Corporation (TSE:7733) for approximately JPY 427.67 billion.

Olympus Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Olympus Announces the Availability of New Monitor Option, the OEV321UH Video Display Monitor

Olympus Corporation Announces Study Results Show Long-Term Efficacy of Itind Procedure

Olympus Corporation to Report Q3, 2023 Results on Feb 10, 2023

Olympus Corporation Announces Dividend for the Year Ended March 31, 2022, Payable on June 3, 2022; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Olympus Corporation to Report Fiscal Year 2022 Results on May 11, 2022

Olympus Announces FDA Clearance of the Celeris Single-Use Sinus Debrider

Olympus Corporation Proposes Board Resignations

Olympus Corporation Revises Consolidated Financial Guidance for the Fiscal Year Ending March 31, 2022

Olympus Corporation (TSE:7733) announces an Equity Buyback for 16,000,000 shares, representing 1.24% for ¥30,000 million.

Olympus Corporation Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022

Accenture Japan Ltd entered into a definitive agreement to acquire Olympus Systems Corporation from Olympus Corporation (TSE:7733).

Olympus Launches Line of Airway Mobilescopes

Olympus Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022

Olympus Corporation Declares Full Year Dividend Ended March 31, 2021

Olympus Launches New Line of Five Single-Use Bronchoscopes

Olympus Corporation to Report Q3, 2022 Results on Feb 04, 2022

Olympus Corporation Announces President and CEO of Olympus to Sign an Absorption-Type Split Agreement with Olympus Medical Science Sales Corporation

Olympus Corporation Launches Comprehensive Global Educational Platform for Healthcare Professionals

Olympus Corporation to Report Q3, 2021 Results on Feb 12, 2021

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin